Document is current
Any future updates will be listed below
-
Authors
Komiya, Yoji
Sugihara, Takahiko https://orcid.org/0000-0002-7181-7494
Ishizaki, Tatsuro
Kimura, Naoki
Kamiya, Mari
Hirano, Fumio
Matsumoto, Takumi
Sasaki, Hirokazu
Hosoya, Tadashi
Tohma, Shigeto
Yasuda, Shinsuke
Matsui, Toshihiro
-
Funding
Funding for this research was provided by:
Ministry of Health, Labour and Welfare (19FE1003)
Ministry of Health, Labour and Welfare (19FE1003)
Japan Agency for Medical Research and Development (21ek0410086h0001)
- License Information
-
More Information
Article History
Received: 9 April 2025
Revised: 4 July 2025
Accepted: 20 July 2025
First Online: 30 July 2025
Declarations
:
: TS has received research grants from Asahikasei Pharmaceutical Co., Daiichi Sankyo Co., Ltd., and Ono Pharmaceutical Co., Ltd. TS has received honoraria from AbbVie GK, Asahikasei Pharmaceutical Co., Astellas Pharma Inc., AYUMI Pharmaceutical Corporation, Bristol Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Mitsubishi-Tanabe Pharma Co., Ono Pharmaceutical, Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., and UCB Japan Co. Ltd. NK has received grants from Novartis Pharma K.K. NK has received honoraria from Eisai Co., Ltd., AbbVie GK, Asahikasei Pharmaceutical Co., Novartis Pharma K.K., Japan Blood Products Organization, Kissei Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Mitsubishi-Tanabe Pharma Co. ST has received research grants from AbbV GK, Chugai Pharmaceutical Co., Ltd. ST has received honoraria from AbbVie GK, Astellas Pharma Inc., AYUMI Pharmaceutical Corporation, Pfizer Japan Inc. TM has received research grants from AbbVie GK, AsahiKASEI Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., and Mitsubishi-Tanabe Pharma Co., TM has received honoraria from AbbV GK, Astellas Pharma Inc., AYUMI Pharmaceutical Corporation, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Gilead Sciences, Inc., Mitsubishi-Tanabe Pharma Co., Ono Pharmaceutical, Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., and UCB Japan Co. Ltd. All other authors have declared no conflicts of interest.
